GRAIL announced that the FDA's advisory panel will meet on September 23, 2026, to review the Premarket Approval application for its Galleri blood test, designed to detect multiple cancers early by identifying cancer-specific methylation patterns. The test aims to detect cancers before symptoms appear, including those without current recommended screenings, and to predict the cancer's origin to guide diagnosis. GRAIL highlights that Galleri is supported by large clinical studies showing increased cancer detection with low false positives and is intended to complement existing screening methods. The FDA designated Galleri as a Breakthrough Device in 2018, and the review marks a significant step toward potentially transforming cancer screening in the U.S.
Strategy, led by Michael Saylor, purchased 4,603 Bitcoin at an average price of $80,318 each in late August 2026, increasing its total Bitcoin holdings to 845,050 BTC. This marks the company's first Bitcoin purchase in 10 weeks after selling nearly 7...
Dell Technologies and NVIDIA both reported strong AI-driven revenue growth in Q2 FY27, with Dell posting $46.97 billion revenue and NVIDIA $96.22 billion. While NVIDIA dominates as the AI compute platform owner with high margins, Dell is gaining grou...
Chevron shares have surged over 42% in 2026, approaching a 52-week high near $212. Strong Q2 earnings, production growth, and debt reduction support the rally, but the stock trades above its price target of $204.67, suggesting limited upside. Bulls p...
The Dividend Harvesting Portfolio achieved a 45.8% return on investment, generating $3,289.51 in annual dividends from a $28,800 investment, with a yield of 7.83%. Recent portfolio additions include Pfizer, valued for its yield above 6% and low earni...
Markel Group announced that Steve Markel will retire as Chairman in 2027, with CEO Tom Gayner stepping into the Chairman role immediately. Simon Wilson and Andrew Crowley have been promoted to Co-Presidents, leading Markel Insurance and Markel Ventur...
